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ABSTRACT 
 
BACKGROUND  
Tuberculosis is the leading opportunistic infection among HIV-infected adults, 
including pregnant women, globally. Accurate screening tools are needed to 
identify those requiring further laboratory testing and to initiate isoniazid 
preventive therapy in a timely manner. This study determined the accuracy of 
symptom-based screening and in particular the performance of the WHO 
recommended TB symptom screening algorithm in HIV-infected pregnant 
women. 
 
METHODS  
 A cross-sectional study was conducted among consenting HIV-infected 
pregnant women attending routine antenatal clinics in Matlosana, South Africa 
recruited >1 week after first HIV diagnosis between June 2010 and February 
2011.  Sputum was collected from all women followed by a systematic TB 
symptom screen. The performances of each symptom (cough, fever, weight loss 
and night sweats) alone and in combination were assessed with TB confirmed 
by sputa using microscopy and liquid culture (MGIT), as reference or gold 
standard. The sensitivity, specificity, positive predictive value, negative 
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predictive value, positive likelihood ratio and negative likelihood ratio were 
calculated for each of the four symptoms (cough, fever, weight loss and night 
sweats) and their combination. Logistic regression was carried out to find 
associations between patient characteristics and TB.  
 
RESULTS 
 Overall, Mycobacteria Growth Indicator Tube (MGIT) confirmed prevalence of 
TB was 2.4% (35/1456) in this sample group. Only 11/38 (29%) women with 
confirmed TB reported any symptoms.  Cough, fever, weight-loss and night 
sweats, individually and in combination had sensitivities ranging from 2.7-27% 
and specificities ranging from 84-97%. The positive predictive and negative 
predictive values for any symptoms of cough, fever, night sweats, or weight loss 
were 4.2% and 98%, respectively. TB was associated with decreasing CD4 count, 
close TB contact, cough, and night sweats. 
 
DISCUSSION 
The remarkable number of asymptomatic TB in HIV-infected patients, including 
in the cohort included in this study highlights the limitation of symptom-based 
screening.  The low sensitivity of the symptom screen would incorrectly stratify 
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patients who are being considered for Isoniazid Preventive Therapy (IPT). 
However, one could argue that the high negative predictive value of the 
symptom screen would justify its use in resource-limited settings as the initial 
step in identifying patients who should receive IPT.  Although household TB and 
the father of the baby having TB were found not to have statistically significant 
associations with active TB, they are of public health importance as they play a 
role in the spread of the infection.   
 
CONCLUSION 
 The WHO 4-symptom screen had low sensitive among HIV-infected pregnant 
women but negative predictive value was high.  Few women with TB disease 
reported symptoms on direct questioning; the high rate of sub-
clinical/asymptomatic TB is concerning.  There is an urgent need for more 
sensitive screening tools for TB in HIV-infected pregnant women.   
 
 
 
 
8 
 
LIST OF TABLES 
Table 1: Synopsis of studies on symptom-based screening 
Table 2: Demographic and clinical characteristics of women in the study 
Table 3: TB point prevalence 
Table 4: Sensitivity, Specificity, Negative Predictive Value, Positive Predictive 
Value, Negative Likelihood Ratio, and Positive Likelihood Ratio of the 
symptoms 
Table 5: Associations with prevalent TB 
NOMENCLATURE and DEFINITIONS 
Accuracy is synonymous to validity and can be defined as “a test’s ability to 
show which individuals have the disease and which do not”. This is usually 
assessed by two estimates, namely Sensitivity and Specificity. 
ANC: Antenatal Clinic 
ARV: Antiretroviral therapy 
AZT: Zidovudine 
CD4: Cluster of Differentiation 4 = Surrogate of Immunity 
CXR: Chest X-Ray 
9 
 
Hb: Haemoglobin 
IPT: Isoniazid Preventive Therapy 
IQR: Interquartile range 
HIV: Human Immunodeficiency Virus 
MGIT: Mycobacterium Growth Indicator Tube 
NLR: Negative Likelihood Ratio 
NPV: Negative Predictive Value, which is a percentage of patients with a 
negative test who do not have the disease. 
PMTCT: Prevention of Mother to Child Transmission 
PLR: Positive Likelihood Ratio 
PPV: Positive Predictive Value, which is a percentage of patients with a positive 
test who actually have the disease.  
Point Prevalent TB is defined as TB present in the cohort of women included in 
the study. It is synonymous to point prevalence. In this study, it includes both 
the TB diagnosed prior to enrolment in the study and previously undiagnosed 
TB confirmed on sputum microscopy or culture. 
 
10 
 
Sens: Sensitivity, which is defined as “the chance of a true positive test. 
Spec: Specificity, which is defined as “the chance of a true negative test”. 
TB: Tuberculosis 
WHO: World Health Organization 
WHO recommended 4 Symptom screen for TB: a symptom screen involving 
presence of any 1 of 4 symptoms of cough, fever, night sweats, or weight loss. 
VCT: Voluntary Counselling and Testing 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Table of Contents 
DECLARATION ................................................................................................... 1 
DEDICATION .................................................................................................. 2  
ACKNOLEDGEMENTS…………………………………………………………………………………….3 
ABSTRACT ...................................................................................................... 4 
BACKGROUND……………………………………………………………………………………….4 
METHODS……………………………………………………………………………………………. 4 
RESULTS………………………………………………………………………………………………..4 
DISCUSSION………………………………………………………………………………………….5 
CONCLUSION………………………………………………………………………………………..5 
LIST OF TABLES…………………………………………………………………………………………….7 
NOMENCLATURE AND DEFINITIONS………..…………………………………………………….7 
CHAPTER ONE: INTRODUCTION……………………………………………………………………9 
1.1 BACKGROUND……………………………………………………………………………………………9 
1.2 LITERATURE REVIEW………………………………………………………………………………..11 
1.3 STATEMENT OF PROBLEM……………………………………………………………………….21 
1.4 JUSTIFICATION OF THE STUDY…………………………………………………………………21 
1.5 AIM AND OBJECTIVES….…………………………………………………………………………..21  
CHAPTER TWO: METHODOLOGY…………………………………………………………………..24 
2.1 PRIMARY DATA SOURCE…………………………………………………………………………..24 
2.2 STUDY DESIGN AND SETTING…………………………………………………………………..25 
2.3 STUDY POPULATION………………………………………………………………………………..26 
2.4 STUDY SAMPLE………………………………………………………………………………………..27 
2.5 DATA COLLECTION…………………………………………………………………………………..27 
12 
 
2.6 STUDY VARIABLES…………………………………………………………………………………...29 
2.7 DATA PROCESSING………………………………………………………………………………….29 
2.8 STATISTICAL ANALYSIS…………………………………………………………………………….28 
2.9 ETHICAL CONSIDERATIONS……………………………………………………………………..29 
CHAPTER THREE: RESULTS……………………………………………………………………………32 
3.1 PARTICIPANT’S DEMOGRAPHIC AND CLINICAL CHARACTERISTICS………….34 
3.2 PREVALANCE OF TUBERCULOSIS (TB)……………………………………………………..35 
3.3 SENSITIVITY AND SPECIFICITY OF SYMPTOMS…………………………………………35 
3.4 ASSOCIATIONS WITH PREVALENT TB………………………………………………………36 
CHAPTER FOUR: DISCUSSION……………………………………………………………………….37 
CHAPTER FIVE: CONCLUSION AND RECOMMENDATIONS………………………….39 
5.1 CONCLUSION………………………………………………………………………………………… 45 
5.2 RECOMMENDATIONS……………………………………………………………………………45 
REFERENCES…………………………………………………………………………………………….47 
APPENDICES...………………………………………………………………………………………….55 
 
 
 
 
 
 
13 
 
CHAPTER ONE: INTRODUCTION 
1.1 Background 
Tuberculosis (TB) remains one of the leading non-obstetric causes of maternal 
mortality globally [1].  It is estimated that one-third of deaths attributable to TB 
occur in women of child-bearing age, mainly in resource-limited countries [1]. It 
was estimated that 700 000 women died from TB in 2008 compared to 342 900 
who died from maternal causes in the same year [2]. TB/HIV co-infection is a 
growing problem in Sub-Saharan Africa [1] and women of childbearing age 
represent a special sub-group of vulnerability because of high HIV prevalence 
rates in this group [3] and higher rates of progression from TB infection to 
disease [4; 5; 6]. TB infection in women of reproductive age impacts not only on 
their own health, but also on the health of both their existing families, as well as 
their unborn children [7]. TB increases the chance of mother to child 
transmission of HIV [8]. 
 
Screening for TB by using a symptom based approach during pregnancy may 
present a diagnostic challenge because early symptoms of the infection are not 
peculiar to TB, and therefore may be attributed to symptoms of pregnancy itself 
[9]. It is important to detect and treat TB early in pregnant women to prevent 
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spread to other people and complications such as disseminated disease, as well 
as death. Early diagnosis would involve screening women for TB during their 
antenatal clinic visits. Antenatal clinic visits could therefore represent a very 
useful point at which to screen for TB, which may go undetected at other points 
in the health system.  
  
The issue of using a symptom based screening approach is well documented 
[10,11,12,13,14,15,16,17,18,19] especially for use in resource-poor settings, 
where the use of chest radiographs and laboratory tests are not always possible 
and are not the most cost effective way to screen.  
 
The South African National Health Department’s guidelines recommend that all 
HIV-infected pregnant women be screened for TB [20]. Screening for TB is 
usually done by asking women about the presence of TB symptoms, which in 
pregnancy may present a diagnostic challenge. Some symptoms can be confused 
with symptoms of pregnancy itself as indicated above, or may  be confounded 
by the condition of pregnancy ( for example weight loss as a symptom of TB 
being confounded by weight gain typical during pregnancy). The use of symptom 
screening for active TB in HIV-infected women is only beginning to be evaluated 
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for its reliability [21; 7]. Screening for TB among pregnant women by the use of 
a limited number of questions during routine antenatal care was found to be a 
feasible alternative to expensive diagnostic investigations in studies carried out 
in Soweto [7; 21]. 
 
1.2 Literature review 
 
TB screening and its evaluation 
The WHO recommends screening of all HIV-infected people for active TB after 
an HIV diagnosis has been made [22]. However, recent global data suggest that 
implementation of screening for tuberculosis in HIV care settings is 
unacceptably low, often as a result of a lack of diagnostic resources [23]. 
 
 A review looking at approaches to screen for TB in people infected with HIV 
highlighted the fact that the best method for screening in resource-limited 
settings is still a matter of considerable debate [24]. The use of symptom-based 
screening for Tuberculosis has been used in a variety of settings. Some of the 
studies which looked at the use of symptom-based screening for active 
tuberculosis are summarised in the table 1 below: 
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Table 1: Synopsis of Studies on Symptom-based Screening 
 Reference  Study population 
characteristics 
Sample 
size 
Results 
Kim et al., 2011 
[25] 
People living with 
HIV/AIDS at 8 
outpatients facilities in 
Cambodia, Thailand, & 
Vietnam. 
1745 Sensitivity for cough in the past 
4 weeks was 94%. 3-symptom 
combination (cough in the past 
24 hours, difficulty in breathing, 
and night sweats for > 3 weeks 
was 85% sensitive and 80 
percent specific.  
Kruk et al., 
2008 [26] 
Children at 3 local clinics 
served by Tygerberg 
Children’s Hospital, 
South Africa. 
252 Negative Predictive Value of 
symptom-based screening 
(cough, fever, fatigue, weight 
loss) varied according to case 
definition used; 95.6% when all 
of the children treated for TB, 
97.2% when only children with 
radiologic “certain tuberculosis’ 
were included, and 100% if the 
case definition excluded those 
with asymptomatic 
uncomplicated hilar 
adenopathy. 
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 Corbett 
 et al., 2010 [27] 
Randomly selected 
participants in a 
community-based TB-
HIV prevalence survey, 
Harare, Zimbabwe. 
1858 
HIV+, 
7121 
HIV- 
 
In HIV+ participants, cough of ≥ 
2 weeks’ duration, any 
symptom (current cough, 
haemoptysis, fever, night 
sweats, and subjective weight 
loss) had sensitivities of 48% 
and 81% respectively. In HIV- 
sensitivities were 45% and 71% 
respectively. Symptoms had a 
higher positive and a lower 
negative predictive value in 
HIV+ participants. 
 Day et al., 2006 
[10] 
Gold miners first 
attending the TB 
preventive therapy 
clinic, South Africa. 
1093 Most sensitive symptom 
combination (59.1%) was any 
night sweats, new or worsening 
cough or reported weight loss, 
measured weight loss > 5% 
increased sensitivity to 90.9%. 
 Mohammed et 
al., 2004 [12] 
HIV+ with WHO clinical 
stage 3 or 4 disease, 
referred for possible 
participation in TB-
preventive therapy trial 
129 Screening instrument of two or 
more of measured weight loss, 
cough, night sweats, or fever, 
had a sensitivity of 100% and 
specificity of 88.1%, and 
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in 3 hospital-based HIV 
clinics, South Africa. 
 
positive and negative predictive 
values of 44% and 100% 
respectively.   
 Den et al., 2006 
[28]. 
Random cluster sample 
of adult’s aged≥ 15, 
Cape Town, South 
Africa.  
1170 Chest X-ray screening had the 
highest sensitivity 0f 97% and 
individual symptoms had low 
sensitivities, ranging from 10% 
for fever  to 54% for cough of ≥ 
2 weeks. 
 Kali et al., 2006 
[21]. 
HIV-infected pregnant 
women, two PMTCT 
program clinics, 
Soweto, South Africa. 
545 Symptoms most associated 
with TB were haemoptysis (OR 
8.26), fever (OR 9.55), weight 
loss > 5kg (OR 5.2), productive 
cough (OR 6.8), chest pain (OR 
4.9), and tiredness (OR 5.1). 
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The studies presented above highlight the usefulness of symptoms for identifying 
active TB. Of note is that they all included participants from different backgrounds. 
In practice they will therefore not be easily comparable in terms of the symptom 
or symptom combination sensitivity and specificity for diagnosing active TB in the 
group of interest in the current study. For example, the study by Mohammed [12] 
included patients with advanced HIV disease which may have a different symptom 
profile than those patients presenting at HIV clinics with relatively recent 
symptoms. All of the mentioned studies used different symptom combinations 
resulting in different sensitivities. Furthermore, different case definitions for TB 
were used, therefore making it difficult to conclude the optimum symptom 
combination to use with which to specific case definition for TB. 
 
The study by Kali et al [21], which included the study participants similar to the 
participants in the current study, showed that haemoptysis, fever, weight loss, 
productive cough, chest pain and tiredness were positively associated with active 
TB. 
A meta-analysis of observational studies by Getahun, et al. [19] found that the best 
performing screening rule was the presence of any one of the following:  
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 Current cough (any duration);  
 Fever; 
 Night sweats: and/or 
 Weight loss.  
The overall sensitivity of this rule was 78.9% and negative predictive value was 
97.7%.[19] TB in pregnancy may prove difficult to diagnose because early 
symptoms of the infection, such as malaise and fatigue may be attributed to the 
condition of being pregnant itself, and may therefore not raise a suspicion of TB 
[29].  
 
Since pregnancy may present a different clinical situation than what is normally 
expected for HIV/TB co-infection, it presents a diagnostic challenge. There is a need 
for further studies to evaluate the accuracy of symptom-based screening 
specifically in this sub-group. Lastly, there may be differences in the timing of 
presentation as well as the resources available to rule out TB between urban and 
rural settings. The study by Nachega et al. [30] investigating a different screening 
strategy (screening by tuberculin skin test) among HIV-infected pregnant women 
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in South Africa, which found TB prevalence of 11% among women in prevention of 
mother to child HIV transmission,  was carried out in an urban setting (Soweto). 
 
Although the above studies demonstrate the usefulness of symptom-based 
screening in a variety of settings among different groups,  the testing of screening 
instruments among the group of interest in this study (HIV infected pregnant 
women) is rare in the available literature, with only the study by Kali et al. [21]  
looking at this particular group.  
 
Women are vulnerable to tuberculosis for a number of reasons. Culture plays a 
major role in the life of women, particularly rural women. Because of gender-based 
roles imposed on women, such as fetching water and firewood and working in the 
fields, women may delay seeking help when sick. McCray [31] found that culture 
left rural women with no ‘’disposable time’’ for them to utilise prenatal care. 
Women in rural and/ or resource-poor settings may encounter specific barriers in 
accessing health care, such as availability constraints caused by long distances from 
the health centres [32] and affordability constraints [33].  Although health services 
are provided free of charge to pregnant women in South Africa, the cost of 
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accessing health care can be high, especially in rural areas [34]. This cost may 
include cost of transport to a health facility, cost of food during the visit, loss of 
income as a result of time spent in a health facility instead of earning a living and 
cost of arranging child minders. For these reasons women may postpone or seek 
help from outside of the formal health care sector. A study by White et al. [35], 
looking at health seeking behaviour among pregnant women in rural Haiti found 
that 25% of women reported not seeking help in the formal health sector and 32% 
of them reported delaying help seeking. 
 
 It is estimated that half of the world’s population uses solid or biomass fuel such 
as wood, coal and paraffin for heating and cooking; and the resultant emissions and 
indoor air pollution are harmful to their health [36]. Rural and/ or resource-poor 
households are often dependent on use of solid fuel, mainly fire wood, which is a 
natural resource, as part of diversified1 livelihood strategy [37]. It is women who 
usually do the cooking and are therefore directly affected by the indoor air 
                                                          
1 Diversification is defined as the process by which households construct increasingly diverse livelihood 
portfolios, making use of increasingly diverse combinations of resources and assets [37]. 
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pollution. Sumpter and Chandramohan [36] found strong evidence for an 
association of indoor air pollution and the risk of Tuberculosis.  
 
Rural women or women from resource-poor settings are likely to be malnourished 
compared to their urban counterparts [38] and malnutrition is one of the identified 
risk factors for developing Tuberculosis [39]  
 
Lastly, HIV infection is associated with an increased risk of contracting TB [40].  As 
the women in our study are HIV-infected, in addition to the other factors 
mentioned above at play, these women are at a particularly high risk of contracting 
TB. 
 
1.3 Problem Statement 
Symptom-based screening is not yet fully evaluated as a reliable tool to be used for 
screening for TB co-infection among HIV-infected pregnant women in South Africa 
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and current screening algorithms need to be tested for accuracy2 (Sensitivity3 and 
Specificity4) for use in this particular sub-group [41, 42] 
 
1.4 Justification of the study  
The study looked at a sample drawn from a rural or resource-poor  area where the 
lack of resources  indicate a particular need for a symptom based screening tool for 
this specific sub-group.    
 
There is a need to combine PMTCT services with active case finding for TB in 
settings where resources are often limited, as antenatal care may be one of the few 
opportunities to screen for TB among HIV-infected pregnant women. Screening by 
symptoms would be more cost-effective and therefore accessible to more people 
in rural and / resource-poor settings, and would also be relevant at different levels 
                                                          
2 Accuracy is synonymous to validity and can be defined as “a test’s ability to show which individuals 
have the disease and which do not”. This is usually assessed by two estimates, namely Sensitivity and 
Specificity. 
3 Specificity is defined as “the chance of a true negative test”. 
4 Sensitivity is defined as “the chance of a true positive test” [43]. 
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of care [24]. The reliability and validity of such a screening tool needs exploration 
for use among HIV-infected pregnant women in different settings. 
1.5 Aim and Objectives 
The aim of this study is firstly, to determine the prevalence of TB co-infection 
among HIV-infected pregnant women attending antenatal clinics in Matlosana in 
2010-2011 and secondly, to determine the accuracy of recorded symptoms (WHO 
4-symptom screen5) in predicting active TB among HIV-infected pregnant women 
attending those clinics  
 
The Specific objectives are: 
 To determine the prevalence of active TB  in the study population 
 To describe the symptoms reported by study participants 
 To determine if associations  exist between symptoms reported and the  
laboratory results (sputum microscopy and/or culture) among HIV positive 
pregnant women attending PMTCT at Matlosana in 2010-2011 
                                                          
5 WHO recommended 4 -Symptom screen for TB: a symptom screen involving presence of any 1 of 4 
symptoms of cough, fever, night sweats, or weight loss 
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 To describe the symptom(s) or symptom combinations that have high sensitivity 
and high negative predictive value for use in screening for TB. 
 To determine the accuracy of the WHO recommended symptom screening 
algorithm in HIV-infected pregnant women for use in resource-limited setting. 
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CHAPTER TWO: METHODOLOGY 
2.1 Primary Data Source 
Data were collected during 2010-2011 at antenatal clinics in Matlosana, as part of 
an earlier study by the Perinatal HIV Research Unit, the aim of which was to assess 
the prevalence of smear and/or culture positive sputum in pregnant HIV-infected 
women in whom their symptoms at screening were also recorded (See Protocol-
appendix 1).  
1456 patients were enrolled using the methods described below. A questionnaire 
was used to collect the data (see Case Report Form appendix-2). Written or verbal6 
consent was obtained. The data was never analysed previously.  
 The original study was approved by the Human Research Ethics Committee 
(Medical) at the University of the Witwatersrand in 2010  
  
                                                          
6 Verbal consent was accepted for the original study by the Human Research Ethics Committee 
(Medical) at the University of the Witwatersrand. 
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2.2 Study design and setting.  
The study is a secondary quantitative data analysis of cross-sectional data collected 
for the original TB prevalence study by Perinatal HIV Research Unit (June 2010 to 
February 2011) as outlined above. 
 
The City of Matlosana is a sub-district in Dr. Kenneth Kaunda district of the North 
West Province and is one of the four local municipalities in this district [44, 45].  The 
Municipality covers an area of 3.162 km2.  The total population was estimated to 
be 398 676 in 2011 (with 1.04% growth rate) [45] with 94% of the population in 
urban settlements and 6 % in rural settlements [46]. Although the majority of the 
area is considered urban, the level of development may be considered to be similar 
to a rural area. The area is divided into 4 towns7, namely, Klerksdorp (46% of the 
population), Orkney (26%), Stillfontein (17%) and Hartebeesfontein (5%); and rural 
settlements (6%) [46]. The main economic activities in this are mining (45%), trade 
(21%) and agriculture (9%). [46]. 
                                                          
7 It is important to note that Orkney, Stillfontein and Hartebeesfontein are small towns that can be in 
fact considered rural. There is no commonly accepted definition of rural in South Africa. 
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Dr. Kenneth Kaunda and Bojanala districts (formerly, Southern and Bojanala 
regions respectively) have the highest HIV Antenatal prevalence rates in the 
province (31.1% and 30.4 % respectively, 2006 data), the provincial rate being 
26.7% [47]  
 
2.3 Study population 
Adult (> 18 years) HIV-infected pregnant women, attending antenatal clinics, in a 
sub-district of Matlosana in 2010-2011. 
Inclusion criteria:  
1. At least 18 years of age. 
2. Pregnant. 
3. Verbal or written consent to participate. 
4. HIV-infected – diagnosed by a two-rapid test algorithm or HIV ELISA at least 
a week prior to the enrolment visit. A record of such testing was required, 
in the form of either an entry in the clinic register or a record on the patient 
held clinic card or a copy of the HIV result with the patient’s name on it. 
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Exclusion criteria 
1. Women unable or unwilling to provide verbal informed consent 
2. Prisoners or other institutionalised women (at the time of recruitment) 
3. Active labour or obstetric or medical complication requiring immediate 
intervention. 
 
2.4 Study sample 
The study analysed 1456 records that were collected in the original Perinatal HIV 
Research Unit study. These records represent all women who qualified for inclusion 
and who were willing to participate at the site. Therefore, there was no sample size 
calculation. Records with missing data were excluded from the analysis. 
 
2.5 Data collection 
 Primary data was collected in the original Perinatal HIV Research Unit study (see 
protocol: appendix 1) in the following way: HIV-infected women attending 
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antenatal services who had been diagnosed with HIV at a previous visit (either 
in the PMTCT Programme or not) and who fulfilled the eligibility criteria were 
approached to provide written or verbal consent to participate in the study by 
a lay counselor involved in the study. The consent to participate was 
documented by the study nurse in the patient’s clinic record and in the consent 
log kept at the clinic. 
 Sputum was collected from the women after consent was given. If a sputum 
sample was not initially obtainable, a supervised induced sputum sample, using 
hypertonic saline, was obtained, paying attention to infection control measures 
(well-ventilated area outside the clinic building for sputum collection). For 
patients from whom sputum could still not be obtained, a specimen bottle was 
provided for an early morning specimen to be brought to the clinic the following 
day. 
 Sputum smear microscopy and mycobacterium culture were performed on all 
specimens using an accredited laboratory. 
 After obtaining the sputum specimens, a systematic TB symptom screening, 
based on the screening method currently proposed by the National 
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Department of Health (see appendix-1), was done by the study nurse. This was 
informed by the previous work done in Soweto but the focus was on major 
symptoms – cough and productive cough, night sweats, fever and weight loss 
or no weight gain [30; 21] 
 Demographic data were also obtained (age, gestational age, TB contact, at least 
two instances of weight recorded in the last three months).  
 Contact details were also recorded in the patient’s clinic record to ensure 
tracing of patients with positive results. 
 Blood for CD4 count was obtained if not done at the time of recruitment   
All data relevant to the answering of the study questions were extracted from the 
original database. 
 
 
2.6 Study variables 
1. The outcome variable was a binary variable showing either active TB confirmed 
on sputum smear microscopy and/or culture (binary outcome) or no active TB. 
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2. The binary outcome variable was tested for association with the following: 
 Demographic data: age (continuous) 
 Clinical characteristics of TB cases:  
o Gestational age of pregnancy (continuous),  
o Weight at current visit (continuous),  
o Weight from previous antenatal clinic visit (continuous) 
o Weight change (continuous) 
o Most recent CD4 count (continuous), 
o TB symptoms and their duration  
 
2.7 Data processing  
Data were extracted from the original database using a data extraction sheet and 
captured into a Microsoft Excel spread sheet. Data was cleaned by removing sets 
with missing variables (symptom data was missing for one and sputum culture data 
was missing for 35 sets). Data was then coded and entered into STATA version 11.1, 
for analysis.  
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2.8 Statistical analysis  
 Descriptive analysis included the patient’s median age in years, median gestational 
age in weeks and median weight in kilograms. The patients were further categorized 
according to the reported symptoms, their CD4 count, the use of AZT for PMTCT, 
current use of antiretroviral treatment, and their TB status. 
The Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive 
Value (NPV) and Positive and Negative Likelihood Ratios of each TB-related symptom 
were calculated with a 95% confidence interval. The performance of each symptom 
independently and in combination was assessed using the prevalence of TB 
confirmed cases in the study population as a reference or gold standard. Microscopy 
and mycobacterial culture, using the BACTEC MGIT 960 system was done on the 
sputum samples. 
 
Logistic regression was carried out to find associations between patient 
characteristics and prevalent TB (previously undiagnosed culture and smear positive 
TB).  For the purpose of this research report, multi-variate analysis was not included. 
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Specificity, Sensitivity, PPV, NPV, PLR and NLR were calculated using a 2 by 2 table 
below [48]. 
 
 
 
 
 Gold standard: 
sputum microscopy 
and/ or culture 
 
 
 
 
 
 S+ S- Total  
 
 
Clinical test: 
Symptom screen 
 
 
T+ 
 
a = True 
positive 
b = False 
positive 
a + b  
 
T- 
 
 
c = False 
negative 
 d = True 
negative 
c + d  
 
 
Total  a + c  b + d   
Sensitivity = a/ (a + b) 
Specificity = d/ (b+ d) 
Positive Predictive Value = a/ (a+ b) 
Negative Predictive Value = d/ (c+ d). 
Positive Likelihood Ratio = Sensitivity / (1 –Specificity) 
Negative Likelihood Ratio = (1 – sensitivity)/ specificity 
 
 
 36 
 
2.9 Ethical consideration 
Ethics clearance for this study was obtained from the Wits Human Research Ethics 
Committee (Clearance certificate M101117. See appendix-4). 
Each patient’s confidentiality was maintained during the course of the study. Unique 
study codes were used for each data point to ensure that no patient identifiers were 
extracted from the original database. 
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CHAPTER THREE: RESULTS 
1456 HIV-infected pregnant women attending antenatal clinics were enrolled. 
Their characteristics are illustrated in table 2. The median age of the women was 
27 years (Interquartile range ((IQR): 23; 32). The median gestational age was 24 
weeks (IQR: 18; 28). The median CD4 count was 396 cells /mm3 (IQR: 277-533). 60% 
of the women were receiving AZT for Prevention of Mother to Child Transmission. 
Only 2 women (0.1%) were receiving antiretroviral therapy for treatment of HIV. 
A notable burden of undiagnosed TB (2.4%) was found in this study. The majority 
of these TB cases were asymptomatic, with only 11/38 women with newly 
confirmed TB having any symptoms. 
Cough was reported by 120 (8%) women, 72 (5%) reported sputum production. 
Fever was reported by 53 (5%) women, night sweats by 52 (4%) women and weight 
loss by 73 (5%) women.  
12 women who were already on TB treatment (0.8%) at enrollment were not 
included in the symptom sensitivity and specificity analysis.  Cough, fever, weight-
loss and night sweats, individually and in combination had sensitivity ranging from 
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2.7-27% and specificity ranging from 84-97%. These four symptoms form part of 
the WHO recommended 4-symptom TB screen. The sensitivity of these symptoms, 
and therefore the WHO recommended 4-symptom TB screen, found in this study is 
considerably low, perhaps due to the small number in our study. The positive 
predictive and negative predictive values for any symptoms of cough, fever, sweats, 
or weight loss were 4.2% and 98%, respectively (table 3). The median CD4 count 
among women with previously undiagnosed prevalent TB was 251 cells/mm3 and 
14 (37%) women with undiagnosed prevalent TB8 had a recent household contact 
with TB disease.   
 In the logistic regression analysis (table 5), some important associations with active 
TB were found in this study (table 5). The odds of getting TB increased with the 
decrease in CD4 count (P < 0.001). Active TB was associated with cough (p=0.003) 
and night sweats (p=0.02).  Household TB and the baby’s father having TB had a 
statistically non-significant association with active TB (p > 0.05). 
 
 
                                                          
8 Prevalent TB (synonymous to point prevalence) is defined as TB present in the cohort of women 
included in the study. It includes both the TB diagnosed prior to enrolment in the study and previously 
undiagnosed TB confirmed on sputum microscopy or culture. 
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Table 2: Demographic and Clinical Characteristics women in the study 
Characteristic  Totals N (%) Median (Range) 
Maternal age, years (IQR)   27 (23-32) 
Gestational age, weeks (IQR)   24 (18-28) 
Weight at screening,  kg   68 (60-80) 
Ever had TB (yes) 114/1453 (8%)  
TB treatment at screening (yes) 12/1453 (1%)  
Anyone at home with TB 362/1455 (25%)  
Childs father with TB now 12/73 (0.16%)   
Mothers smokes 41/1455 (25%)  
Median Hb at screening   11.2 (10.1 - 12.4) 
CD4  (most recent)  396 (272 -  533) 
CD4 group count (most recent)    
≤ 200 185 (13)  
201-300 249 (17)  
 301-400 294 (21)  
401-500 263 (18)  
˃ 500 436 (30)  
Antiretroviral management at screening    
AZT pMTCT 881/1455 (60%)  
Current ART 2/1455 (0.1%)  
No ART 572/1455 (39%)  
Prior ANC visit (yes) 1424/1455 (98%)   
Participants reporting:    
Cough > 1 day 120/1455 (8%)  
Cough > 2 weeks  62/1455 (4%)  
Sputum production 72/1455 (5%)  
Coughing of blood or blood-stained sputum 11/1455 (1%)  
 Night sweats  52/1455 (4%)  
Weight loss (self-reported) 113/1342 (8%)  
Weight loss > 2kg (from prior ANC visit) 73/1455 (5%)    
Tiredness  53/1455 (3.6%)  
Swellings in the neck, armpits or elsewhere 43/1455 (35%)  
Chest pains, fast breathing, dyspnoea 36/1455 (2.5%)  
Fever 53/1455 (4%)  
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 Table 3: TB point prevalence 
Diagnosed prevalent TB 12/1456 (0.8%) 
Undiagnosed prevalent TB (culture positive) 35/1456 (2.4%) 
Undiagnosed  prevalent TB (smear positive & CXR 
confirmed) 
1 
Undiagnosed  prevalent TB (smear positive, No CXR) 2 
Total TB at screening) 49/1456 (3.3%) 
 
 
Table 4: Sens, Spec, NPV, PPV, NLR, and PLR of the symptoms 
Symptoms/ 
Symptoms 
combination 
Participants 
with 
defined 
symptoms 
 
 
Participants 
with 
defined 
symptoms 
without TB 
TB cases 
with 
defined 
symptoms 
  
Spec% Sens% 
 
 
NPV PPV  NLR PLR 
Cough (C) 115 107 8 92 22 98 7.0 0.85 2.8 
Fever (F) 52 51 1 96 2.7 97 1.9 1.0 0.74 
Weight loss 
(W) 
109 106 3 92 8.1 97 2.7 0.99 1.1 
Night 
sweats (S) 
50 46 4 97 11 98 08.0 0.92 3.3 
CFSW 237 227 10 84 28 98 4.2 0.87 1.7 
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Table 5: 2 by 2 table for calculation of Sens, Spec, PPV, and NPV for CFSW. 
 
 
 
 
 Gold standard: 
sputum microscopy 
and/ or culture 
 
 
 
 
 
 S+ S- Total  
 
 
Clinical test: 
Symptom screen 
 
 
T+ 
 
a = True 
positive 
10 
b = False 
positive 
227 
a + b  
 
237 
 
T- 
 
 
c = False 
negative 
 
25 
 d = True 
negative 
 
1152 
c + d  
 
 
Total  a + c  
35 
b + d  
1379 
 
 
Below is few Calculations to show how the values were obtained using CFSW as an 
example. In reality the calculations are done by STATA software.  
Sensitivity = 10/ 35 = 28% 
Specificity = 1152/ 1374 = 84% 
PPV = 10/ 237 = 4.2% 
NPV = 1152/ 1177 = 98% 
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Table 6: Associations with point prevalent TB (undiagnosed at screening): logistic 
regression 
  OR (95% CI) P-Value 
CD4    
<200 1 < 0.001 
  
  
  
  
200-300 0.47 (0.21 -  1.1) 
301-400 0.11 (0.033 - 0.41) 
401-500 0.17 (0.057 - 0.53) 
>500 0.13 (0.047 - 0.36) 
Hb 
≤ 10 g/dL 1.1 (0.50 - 2.3) 0.8 
  > 10g/dL 1 
Previous TB  
No  1 0.3 
  Yes  0.32 (0.043 - 2.4) 
Household with TB  
No  1 0.1 
  Yes  1.7 (0.85 - 3.3) 
Baby’s father with TB 
No  1 0.9 
  Yes  1.0 (0.25 - 4.5) 
Mother smokes    
No  1 0.4 
  Yes  2.0 (0.46 -  8.6) 
Cough   
No  1 0.003 
  Yes  3.3 (1.5 - 7.5) 
Night sweats  
No  1 0.02 
  Yes  3.6 (1.2 - 10) 
Weight loss  
No  1 0.9 
  Yes  1.1 (0.33 - 3.6) 
Fever  
No  1 0.8 
  Yes  0.74 (0.099 - 5.5) 
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CHAPTER FOUR: DISCUSSION 
This study found pulmonary TB prevalence of more than three percent, which is 
moderately high as compared to the prevalence found in HIV negative patients from 
a high TB burden community [14].  2.4% of the cases of TB were undiagnosed prior 
to the study.  A previous study done in Soweto also showed a high burden of TB 
among HIV-infected pregnant women attending voluntary counselling and testing 
(VCT) sessions for HIV [21]. The noteworthy prevalence of undiagnosed TB in this 
cohort is in keeping with generally high levels of undiagnosed TB reported among 
HIV-infected patients. Bassett, et al., found that nearly 20% of patients starting ART 
in Durban had undiagnosed, culture positive TB [49]. Active TB is strongly associated 
with increased mortality risk [50] and undiagnosed TB is associated with the risk of 
transmission to the unborn baby and to other patients in crowded clinic settings [51], 
which is a common reality in South Africa and these patients remain reservoirs of TB 
in the community. 
 
Women have specific additional factors which predispose them to contracting HIV 
and developing TB. The factors which make women vulnerable to HIV and TB occur 
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at individual, societal, health systems and political levels. As such, multidisciplinary, 
broad-based strategies, addressing social determinants of health would need to be 
used in order to address these factors. Lὃnnroth et al. [58], have highlighted the 
importance of addressing the underling risk factors of TB as well as social 
determinants in the current TB strategies in order to reach long-term control 
targets. They suggest the framework below (Figure 1): 
Figure 1:  Framework for proximate risk factors and upstream determinants of 
TB [58]. 
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The high level of TB in HIV-infected patients re-emphasizes the need for an accurate, 
cheap and easy to use screening tool for use during antenatal visits. Hence, there 
was a need to determine the specificity and sensitivity of the symptom-based 
screening for early TB in women attending antenatal care in order to treat those with 
active TB and offer Isoniazid Preventive Therapy to those with no TB [52]. In 
resource-poor settings it is not always possible to use the diagnostic tools such as 
microscopy and culture to rule out tuberculosis. Symptom-based screening has been 
shown to offer an alternative to high- technology tools in screening for tuberculosis 
[53] and the new joint guidelines on Isoniazid and intensified case-finding from WHO 
state that screening for tuberculosis by using only a symptom-based screening 
algorithm is sufficient to start Isoniazid Preventive Therapy (IPT) for people living 
with HIV [54]. 
 
Tuberculin Skin Test has been used in resource-poor settings previously to screen 
patients for active TB. Those who were found to have a positive reaction were then 
investigated further for active TB [30). In our setting where BCG is widely used, there 
might be issues of false positive results. 
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The main aim of this study was to determine the accuracy of reported symptoms 
in predicting TB among HIV-infected pregnant women attending antenatal clinics 
in a resource-poor settings, using the prevalence of TB confirmed cases in the study 
population as a reference or gold standard. The study by Kali, et al. [21], showed 
that haemoptysis and fever were the symptoms most associated with TB in HIV-
infected women. In this study, the majority of women with confirmed TB reported 
no symptoms suggestive of TB. The high level of subclinical TB in this population 
made it difficult to determine whether a relationship existed between TB 
symptoms and confirmed TB. The sensitivity of the symptoms was too low to be 
useful in diagnosing TB in this population. Thus the 4-symptom screen 
recommended by the World Health Organization, was only useful in ruling out TB 
(as seen by the high negative predictive value), but performed poorly in diagnosing 
TB, even in participants who had smear-positive TB (as seen by a poor sensitivity). 
The reality in practice is that relying only on a symptom screen will miss a large 
number of patients who need treatment.  
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The symptom-based screening will continue to be of value in stratification of 
patients in terms of their likelihood of not having TB, such that in those without any 
symptoms, which would constitute a negative screen test, the likelihood of having 
TB would be low and that they could be started on IPT. The negative predictive 
value for cough, fever, weight loss and night sweat and all the four symptoms 
combined ranged from 97% to 98%.  
 
The symptom screen however would have limitations in those who are at an 
increased risk of developing TB, such as HIV-infected patients; and in those where 
the symptoms of TB could be masked by other conditions, such as pregnancy, in 
which case further investigations including sputum microscopy and/or culture 
would still be required. The high level of asymptomatic TB in this study highlights 
this limitation. A meta-analysis of intensified case finding for HIV-associated TB 
found that microbiological examination of sputum from all HIV-infected persons, 
without prior selection by symptoms screening yields an additional 4 cases per 100 
individuals screened, compared to when the symptoms were used to trigger 
microbiological examination [55]. 
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In resource poor settings, symptom-based screening should be the starting point. 
The utility of the 4 symptom screen recommended by World Health Organization 
has been proven in other studies, including the meta-analysis by Getahun et al, [19] 
and this study reaffirms its high negative predictive value in HIV-infected pregnant 
women. HIV-infected pregnant women who are categorized by the 4 symptom 
screen as less likely to have tuberculosis can be started on Isoniazid Preventive 
Therapy. The health care providers should however bear in mind that not all women 
with active tuberculosis would have any symptoms and that the screen needs to be 
repeated on subsequent visits. Close monitoring of the women who are HIV-infected 
is required and if in doubt, sputum should be taken for microscopy, culture and / or 
Xpert MTB/RIF9 assay, if this test is available. 
 
Although found not to be statistically significant in the current study, household TB 
and the father of the baby having TB, are associations of public health importance 
in the context of South Africa. Overcrowding is not uncommon in South Africa.  
                                                          
9  Xpert MTB/RIF assay is a real-time PCR assay for Mycobacterium tuberculosis that simultaneously 
detects rifampicin resistance (Cepheid, Sunnyvale CA, USA) [59]. 
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Having a household TB contact would increase the chance of HIV-infected pregnant 
woman contacting the infection as close social interaction and overcrowding may 
play a role in the transmission [56]. Mining is one of the major economic activities 
in Matlosana Sub-district [46]. TB is epidemic among workers in South African gold 
mines [57]. Some of the men who are fathers of the babies and employed in the 
gold mining sector may be exposed to TB, and in turn expose their partners to it. 
 
 There are some limitations in this study inherent to the design of the primary study. 
Firstly, this study was only limited to one South African setting and therefore the 
results would not be generalizable to all HIV-infected pregnant women in resource-
poor settings; however one could expect similar results in other contexts.  
 
Secondly, the sample size was predetermined by the primary study and therefore 
power calculation for this study was not done prospectively as the study was 
secondary data analysis. However the power calculation could have been done 
retrospectively.  The number of women included in the study proved to be small.  
Only a small number of women who had TB reported symptoms. The few reported 
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symptoms were not sufficient to allow determination of the accuracy of different 
symptom combinations in addition to the WHO 4-symptom screen. 
 
Thirdly, only one sputum sample was collected. This would have an impact on the 
chance of finding acid-fast bacilli on microscopy and may also have an impact on the 
culture yield. Multiple and especially early morning specimens would have been 
ideal. 
 
Lastly, there was a chance of bias in our study. This includes selection bias and recall 
bias. In terms of the selection bias, only women who attended the antenatal clinic 
were included in the study. These women may be different to the women in the 
general population. Selection bias may arise from the fact that women who have 
more advanced disease may recall the presence of symptoms better compared to 
those who have mild disease or those who are at an early stage of the disease.  This 
might influence the accuracy of symptom-based screening as the tool is dependent 
on the participant’s recollection of their disease experience.  
One of the lessons learned from this study is that all women who are HIV-infected 
and therefore at a significant risk of having TB, will need to have their sputa taken 
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for microscopy and culture, in addition to the symptom screen. This will ensure that 
those who are not having an active disease receive the necessary isoniazid 
prophylaxis to prevent them from getting an active disease and that those with an 
underlying but subclinical TB will not be missed and given the necessary treatment. 
 
This study is one of the few studies which looked at the accuracy of symptoms-
based screening for TB in HIV-infected pregnant women. 
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CHAPTER FIVE: CONCLUSION AND RECOMMENDATIONS 
5.1 CONCLUSION 
There was a high prevalence of asymptomatic TB in the group of women enrolled 
in the study. Symptom-based screening had low sensitivity in HIV-infected 
pregnant women attending antenatal clinics in Matlosana. This means that the 
symptom screen could not accurately identify all women who had active 
tuberculosis as diagnosed by microscopy and/or culture. Negative predictive value 
was however high which means the 4 symptom screen could be used to identify 
women who are less likely to have active tuberculosis and therefore eligible for 
Isoniazid preventive therapy. 
5.2 RECOMMENDATIONS 
The following are recommended, which cut across the individual, health system, 
and policy levels: 
1. All HIV-infected women should have their sputa taken for exclusion of TB 
in addition to the symptom screen as part of PMTCT. A new diagnostic 
algorithm would be needed to take into account the use of Xpert MTB/RIF 
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test for diagnosis of TB and Multidrug resistance. A study done in South 
Africa and other low income countries to evaluate the feasibility, 
diagnostic accuracy and effectiveness of decentralized use of Xpert 
MTB/RIF test for TB diagnosis and multidrug resistance found that the test 
can effectively be used in low-resource settings to simplify patient’s 
access to early and accurate diagnosis, thereby potentially decreasing 
morbidity associated with diagnostic delay in the case of microscopy and 
culture [59].  
2. Women who are found to have a negative symptom screen may be 
started on IPT. Even in these women, sputa should be considered if in 
doubt and the screen should be repeated on each subsequent visit.  
3. Further research looking at more accurate diagnostic test for TB in 
resource-poor settings is essential. 
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Introduction 
 
HIV and tuberculosis (TB) have emerged as a leading infectious cause of death among women of 
reproductive age worldwide (6-13). Current approaches to TB control are failing in areas with a 
high prevalence of HIV (2, 3).  Active case finding in settings with a high prevalence of HIV 
could be necessary to strengthen TB control programs. Research has shown that tuberculosis is a 
significant cause of infant and maternal morbidity and mortality. Co-infection with TB and HIV 
increases vertical transmission of HIV (9, 11). 
 
Effective strategies to control TB include early identification and treatment of active cases of 
TB, providing prophylaxis to patients with latent TB infection, and infection control to reduce 
transmission of TB. In South Africa there is a high prevalence of undiagnosed, active TB among 
HIV-infected persons; therefore it is likely that targeting HIV-infected adults would strengthen 
TB control programs. Settings with a known higher prevalence of HIV include hospitals, clinics, 
HIV testing and counseling centers, HIV clinics, TB Clinics, STI clinics and prisons (1, 4, 5). 
Women presenting to antenatal clinics are also at a higher risk for HIV.   
 
Perinatal transmission of TB to a neonate may occur through intrauterine, intra-partum or 
postpartum transmission. Intrauterine transmission of TB occurs via hematogenous spread 
through the umbilical vein or via inhalation and ingestion of TB contaminated amniotic fluid. 
Intra-partum transmission of TB occurs through inhalation or ingestion of amniotic fluid or 
genital secretions. Postpartum transmission of TB occurs primarily through inhalation or 
ingestion of respiratory droplets from the mother or through infected breast milk. Infants with 
perinatal TB have high mortality – up to 38% (9). Perinatal TB is also associated with an 
increased risk of HIV transmission from mothers with HIV/TB co-infection (9).  The prevalence 
of TB in pregnancy at King Edward VIII Hospital in Durban, South Africa in the late 1990s was 
775/100,000 among HIV-infected women (12). Among HIV-infected women at an antenatal 
clinic at Chris Hani Baragwanath Hospital in 2001, about half were TB skin positive, and among 
these, 11% had active TB (10). 
 
Tuberculosis is a significant cause of maternal mortality. In a study of over 50,000 deliveries in 
Durban, South Africa, the mortality rate among those with tuberculosis and HIV co-infection 
was 121.7/100,000 (8). Tuberculosis was the third leading cause of maternal mortality after 
sepsis and hypertensive disorders of pregnancy (8).  
 
Tuberculosis is also a significant cause of infant morbidity and mortality. In a small prospective 
study of 82 HIV/TB co-infected women and 25 HIV-uninfected and TB-infected women at King 
Edward VIII Hospital in Durban, South Africa, the perinatal mortality among neonates born to 
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HIV/TB co-infected women was 85.4/1,000 (13). The rate of vertical-transmission of TB was 
16%, with no difference between HIV-infected and HIV-uninfected women. 66% of neonates 
born to women with TB had intrauterine growth retardation (13). 49% of neonates born to 
women with TB had low birth weights (13). Infants born to HIV/TB co-infected women at a 
large, urban, public teaching hospital in Pune, India were found to have a 3-fold increased 
mortality rate compared to infants born to HIV-infected women without TB (6). 
 
Vertical transmission of HIV also appears to be impacted by co-infection of the mother with 
tuberculosis. In a study of 42 women in Durban, South Africa with HIV/TB co-infection, the 
intrauterine transmission rate of HIV was 19%, compared to the 5-10% observed among HIV-
infected women in resource-limited settings (11). 
 
Different approaches have been used to screen for TB including: symptom screening, TB skin 
testing, sputum smear microscopy, mycobacterial culture and chest x-ray. Some investigators 
have screened only HIV-infected women for TB during the peripartum period, while others have 
screened all women for TB during the peripartum period. In Soweto, the prevention of mother to 
child transmission program tests about 30 000 women per annum of whom approximately 30% 
are found to be HIV-infected of whom almost all receive an intervention to prevent MTCT of 
HIV.   In 2009, our group completed a study of the prevalence of TB in HIV-infected and 
uninfected pregnant women in six of the 13 antenatal clinics in Soweto.  In that study we showed 
that in HIV-infected women the prevalence of previously undiagnosed pulmonary TB was 
696/100,000 and (10 cases), and in HIV-uninfected pregnant women (5 cases) 200 per 100,000 .  
The Soweto prevention of mother-to-child transmission of HIV (PMTCT) program is offered in 
13 community clinics and a hospital-based antenatal clinic in Soweto. The PMTCT program tests 
approximately 30,000 pregnant women per year, of whom about 30% are HIV-infected (7).   
 
The feasibility of active case finding for tuberculosis has been studied in two community clinics 
in Soweto where the PMTCT program is offered (7). Women found to be HIV-infected were 
then screened for active symptoms of TB during their post-counseling session, and if their 
symptom screen was positive, they were tested for TB with sputum smear and mycobacterial 
culture. The prevalence of active TB was 2%, none of whom were sputum smear positive (7). 
The acceptance rate for TB screening during post-test counseling was low (66%). The authors 
hypothesized that the informed consent procedure and need for additional phlebotomy may have 
decreased acceptance rates. They also conjectured that having just learned they had HIV, these 
women were reluctant to be tested for another serious disease (7).  In our prevalence study in 
Soweto, we therefore used verbal consent at the pre-test HIV counseling session and uptake to 
that study was close to 100% of the women approached.    
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However, concern has recently been expressed about “asymptomatic” or “sub-clinical” TB in 
HIV-infected adults. In a study from Ethiopia by Shah, 15% of HIV-infected adults diagnosed 
with TB were found to be asymptomatic.    Our previous study used the presence of symptoms to 
identify women who then had a smear and mycobacterial culture performed on a sputum 
specimen.  However, asymptomatic pregnant women were not included.    In the proposed study 
we will assess the prevalence of pulmonary TB in pregnant women - irrespective of whether or 
not they have symptoms suggestive of TB.    
 
 
Objectives 
 
Primary objectives 
o To assess the prevalence of smear and/or culture positive sputum in pregnant HIV-infected 
women stratified by reported symptoms.   
 
Methodology 
 
Sites: Antenatal clinics in Matlosana 
 
Population: HIV-infected pregnant women attending antenatal PMTCT services.   
 
Eligibility: 
 
Inclusion Criteria: 
1. At least 18 years of age.  
2. Pregnant 
3. HIV-infected - diagnosed by a two-rapid test algorithm or HIV ELISA at least a week 
prior to the enrollment visit.  Some form of documentation will be required – either an 
entry in the clinic register or a record on the patient held clinic card or a copy of the HIV 
result with the patient’s name on it.   
4. Verbal or written consent to participate. 
 
 
Exclusion Criteria: 
1. Women unable or unwilling to provide verbal informed consent. 
2. Prisoners or other institutionalized women (at the time of recruitment). 
3. Active labour or obstetric or medical complication requiring immediate intervention. 
4. Taking HAART at the time of enrollment 
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Study Procedures: 
 
HIV-infected women attending antenatal services who have been diagnosed with HIV at a 
previous visit (either in the PMTCT program or not) and fulfilling other eligibility criteria will be 
approached to provide written or verbal verbal consent by the lay counselor involved in the study 
to participate in this study.  Consent to participate will be documented by the lay counselor in a 
source document.  No signature will be required or obtained from the participant.    
 
Sputum Specimen:  Once verbal consent has been obtained and documented, a sputum specimen 
will be obtained from the pregnant women.  If a sputum sample is unable to be obtained, a 
supervised induced sputum sample will be obtained using nebulised hypertonic saline. For 
infection control purposes, nebulization procedures will be performed in a well ventilated area, 
such as outside of the clinic building.  If no specimen is obtained, a specimen bottle will be 
provided with a request for an early morning specimen to be brought to the clinic the following 
day. Sputum smear microscopy and mycobacterial culture will be performed on all specimens 
from symptomatic women using an accredited laboratory.  
 
If a woman is identified as having active pulmonary TB, she will be contacted and referred to the 
nearest TB treatment facility in her area for TB treatment.  Drug susceptibility testing for 
isoniazid and rifampin will be performed if the culture specimen is suitable. 
 
Symptom screening: At the visit when the sputum specimen is obtained, after obtaining the 
sputum specimen, a systematic TB symptom screen will be administered based on the one 
currently proposed by the National Department of Health. Symptom screening for active 
pulmonary TB will be performed by a lay counselor.   This will be informed by our previous 
work in Soweto but will focus on the major symptoms – Cough and productive cough, night 
sweats and weight loss or no weight gain will feature prominently.   
 
Investigations: The participant’s CD4 count will be recorded but if not done at the time of 
recruitment, a blood specimen will be taken at that visit and the result provided to the woman 
and recorded on her antenatal record within two weeks of it being taken. If CD4 count is less 
than 350 cells the pregnant woman will be immediately referred for initiation of highly active 
antiretroviral therapy (HAART).  Similarly if the CD4 count is above 350 and not already taking 
azothiaprine (AZT), the woman will be referred for AZT initiation.  This study will not provide 
antiretrovirals for pregnant women.   
 
Demographic Details:  Women’s age, gestational age, most recent known contact with a case of 
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TB, prior episodes of TB, month of first diagnosis of HIV and at least two documented weights 
in the past three months will be will be recorded for analytical purposes.  As will the clinic where 
she was enrolled.   In addition, contact details: contact cell phone number and address will be 
recorded in the source document to ensure that if a specimen is found to be positive, the woman 
can be re-contacted and referred for TB treatment.  Contact details will not be collected for 
analytical purposes.      
 
Referral: Women diagnosed with active TB will be contacted and referred to their most 
convenient TB Clinic for TB treatment after being notified. We will not provide treatment for TB 
as part of this study. We will follow the women with active TB to verify that they follow up in 
TB Clinic. If necessary, the study coordinator will make home visits to make sure that the 
women receive their test results and to encourage them to follow up in TB Clinic. 
 
Sample size estimation: The prevalence of HIV in the antenatal clinics in Matlosana is 
approximately 33%, resulting in 2000 HIV-infected pregnant women being diagnosed with HIV 
annually in the PMTCT programme.   In our previous symptom-based study, we found that six 
percent [600 cases per 100 000] of pregnant, HIV-infected women had active TB. From prior 
reports in non-pregnant adults, we assume that this figure could be elevated by 10% to 660 cases 
per 100 000 population in the Matlosana district. Moreover, we expect the TB prevalence may be 
even higher as a proportion of women may be asymptomatic at screening.  For the purposes of 
this study we assume that a further 15% of cases were asymptomatic or sub-clinical.  We 
therefore estimate that 7.6% of HIV-infected pregnant women in the Matlosana district will have 
active pulmonary TB. We will recruit 1500 HIV-infected pregnant women and estimate that 114 
will have active TB of whom 15 will be asymptomatic.  We will report the prevalence of active 
pulmonary TB with 95% confidence intervals in pregnant women, stratified by whether or not 
they had symptoms suggestive of TB.   
 
Ethical issues 
We will be obtaining written or if someone does not want to sign consent but syill wants to be in 
the study verbal consent will be accepted from pregnant women for participation in the study.  
We feel it is appropriate to do so because our intervention is not invasive.  Moreover, we the 
questions we will ask of the women are not intrusive but relate to TB and will be asked in a 
private room.  A dated record of obtaining verbal consent will be made in the source document 
by the lay counselor who discussed the study with the participant.  In response to concerns of the 
local IRB, a consent log will be maintained at each site of recruitment.   
 
Timeline 
We anticipate Ethics approval will be obtained for this study by end January 2010.  Site 
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preparation and study nurse recruitment will also take place in January 2010.  First enrollment of 
pregnant women will be in February 2010.  We will recruit approximately 150 HIV-infected 
pregnant women each month for 10 months.  Results will be available end November 2010.  
Meetings will be held on site with National TB Control Personnel in March, June and September 
2010.   
 
 
Budget 
This study is funded by a grant from the National Department of Health TB Control Programme 
 
LABORATORY Number Cost/item ZAR 
Auramine smear 1500 75.1  R112,650.00  
MGIT Culture 1500 104.85  R157,275.00  
ZN stain for 
mycobacterial 
culture positive 25 27  R675.00  
Speciation of 
mycobacterial 
culture pos 25 250  R6,250.00  
    R276,850.00  
SALARY    
Study Nurse 10 14500  R145,000.00  
    
SUPPLIES    
Stationary 1 8012  R8,012.00  
Ethics submission 1 1000  R1,000.00  
Transport 10 2200  R22,000.00  
telephony 10 400  R4,000.00  
translations 3 1000  R3,000.00  
    R38,012.00  
    
SUBTOTAL    R459,862.00  
    
Wits Health Consortium Indirect (8%)  R36,788.96  
    
TOTAL    R496,650.96  
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